Psilocybin research shows potential for treating addiction and eating disorders

New clinical research is exploring the therapeutic potential of psilocybin, the active ingredient in magic mushrooms, for various mental health and addiction challenges. In the United Kingdom, researchers from Imperial College London reported promising results in a trial involving women with anorexia nervosa. Following six weeks of psilocybin administration paired with intensive psychotherapy, 18 out of 21 participants showed a reduction in eating disorder scores, with nearly half maintaining scores comparable to those without eating disorders after one year.

Other studies are investigating psilocybin as a tool to combat cocaine addiction. In a controlled trial of 40 participants, a single administration of the molecule combined with psychotherapy was linked to increased abstinence days and a lower probability of relapse, offering a potential solution for stimulant use disorders where no validated pharmacological treatments currently exist.

Despite these developments, significant barriers to widespread use remain. In Australia, where psilocybin was approved for treatment-resistant depression in 2023, high therapy costs—ranging from $15,000 to $30,000—have limited patient access. Additionally, researchers face challenges in conducting gold-standard clinical trials, as the psychoactive effects of the substance make double-blind placebo testing difficult.